Hennion & Walsh Asset Management’s Heron Therapeutics HRTX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-138,200	Closed	-$583K	–	784
2022 Q3	$583K	Sell	138,200 -7,808	-5%	-$30.6K	0.04%	450
2022 Q2	$407K	Sell	146,008 -137,946	-49%	-$554K	0.03%	535
2022 Q1	$1.62M	Sell	283,954 -12,098	-4%	-$88.5K	0.09%	249
2021 Q4	$2.7M	Sell	296,052 -71,065	-19%	-$726K	0.13%	198
2021 Q3	$3.92M	Sell	367,117 -13,125	-3%	-$160K	0.21%	132
2021 Q2	$5.9M	Sell	380,242 -13,239	-3%	-$211K	0.31%	73
2021 Q1	$6.38M	Buy	+393,481	New	+$7.01M	0.38%	61

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Hennion & Walsh Asset Management's HRTX Position: Q4 2022 in Review

Hennion & Walsh Asset Management sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 138,200 shares — an estimated $583K sold.

Hennion & Walsh Asset Management first reported a position in HRTX in Q1 2021 and held it in 7 quarters. The position peaked at $6.38M in Q1 2021. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

Hennion & Walsh Asset Management reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
Hennion & Walsh Asset Management sold 138,200 Heron Therapeutics shares in Q4 2022, an estimated $583K.
Hennion & Walsh Asset Management first reported a position in Heron Therapeutics in Q1 2021 and held it in 7 quarters.
Hennion & Walsh Asset Management's Heron Therapeutics position peaked at $6.38M in Q1 2021.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Hennion & Walsh Asset Management's 13F filing for Q4 2022, filed 12 Jan 2023.